Asia Pacific Laboratory Developed Tests Market Size, Share & Trends Analysis Report By Technology (Immunoassays, Molecular Diagnostics, Flow Cytometry), By Application, By Country, And Segment Forecasts, 2025 - 2030
This report can be delivered to the clients within 3 Business Days
Asia Pacific Laboratory Developed Tests Market Growth & Trends
The Asia Pacific laboratory developed tests market size is anticipated t%li%reach USD 3.94 billion by 2030 and is anticipated t%li%grow at a CAGR of 6.4% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc. The region is witnessing a significant surge in cancer incidence, with an estimated 3.25 million new cases in China in 2024, 1 million new cases in Japan annually, and a projected 1.5 million cases in India by 2025. This trend has created a substantial demand for specialized diagnostic tests, driving the development of laboratory-developed tests (LDTs) tailored t%li%specific patient needs and conditions.
China's implementation of Order 739 in 2021 has facilitated increased development of LDTs, while regulatory reforms in Japan, India, and Australia aim t%li%streamline the approval process for diagnostics, including LDTs. Moreover, significant investments in laboratory automation technologies have enhanced efficiency and accuracy in testing procedures, making LDTs more appealing t%li%healthcare providers.
The growing trend towards automation in laboratories has been pronounced in major hospitals in China and Japan, with adoption rates increasing by approximately 15% annually. Collaborative initiatives among academic institutions, research centers, and healthcare organizations in countries such as Japan and South Korea are driving innovation, enhancing the quality of diagnostic tests, and supporting market growth.
Asia Pacific Laboratory Developed Tests Market Report Highlights
Asia Pacific Laboratory Developed Tests Market Growth & Trends
The Asia Pacific laboratory developed tests market size is anticipated t%li%reach USD 3.94 billion by 2030 and is anticipated t%li%grow at a CAGR of 6.4% from 2025 t%li%2030, according t%li%a new report by Grand View Research, Inc. The region is witnessing a significant surge in cancer incidence, with an estimated 3.25 million new cases in China in 2024, 1 million new cases in Japan annually, and a projected 1.5 million cases in India by 2025. This trend has created a substantial demand for specialized diagnostic tests, driving the development of laboratory-developed tests (LDTs) tailored t%li%specific patient needs and conditions.
China's implementation of Order 739 in 2021 has facilitated increased development of LDTs, while regulatory reforms in Japan, India, and Australia aim t%li%streamline the approval process for diagnostics, including LDTs. Moreover, significant investments in laboratory automation technologies have enhanced efficiency and accuracy in testing procedures, making LDTs more appealing t%li%healthcare providers.
The growing trend towards automation in laboratories has been pronounced in major hospitals in China and Japan, with adoption rates increasing by approximately 15% annually. Collaborative initiatives among academic institutions, research centers, and healthcare organizations in countries such as Japan and South Korea are driving innovation, enhancing the quality of diagnostic tests, and supporting market growth.
Asia Pacific Laboratory Developed Tests Market Report Highlights
- Based on technology, molecular diagnostics dominated the market with a revenue share of 20.0% in 2024, owing t%li%its vital role in rapid pathogen detection and timely treatment decisions.
- Immunoassays are expected t%li%grow at the fastest CAGR over the forecast period.
- Based on application, the oncology segment led the market in 2024, underscoring the need for advanced diagnostics such as LDTs. Innovations such as NGS and PCR have enhanced cancer diagnostics.
- Nutritional and metabolic diseases are projected t%li%witness the fastest CAGR from 2025 and 2030. As aging populations in countries such as Japan and China are more vulnerable t%li%these conditions, increasing the demand for specialized assessments.
- Based on region, China held the largest revenue share in the Asia Pacific laboratory-developed tests market in 2024, fueled by government initiatives and advancements in diagnostics, addressing the rising demand for personalized healthcare solutions for China’s aging population.
- In May 2024, Guardant Health secured EU IVDR certification for Guardant360 CDx in Europe, facilitating expanded genomic profiling of solid tumors and potentially prompting similar regulatory developments in Asia Pacific countries.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Application
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. ASIA PACIFIC LABORATORY DEVELOPED TESTS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. ASIA PACIFIC LABORATORY DEVELOPED TESTS MARKET: TECHNOLOGY BUSINESS ANALYSIS
4.1. Technology Market Share, 2024 & 2030
4.2. Technology Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. Immunoassays
4.4.1. Immunoassays Market, 2018 - 2030 (USD Million)
4.5. Hematology and Coagulation
4.5.1. Hematology and Coagulation Market, 2018 - 2030 (USD Million)
4.6. Molecular Diagnostics
4.6.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
4.7. Microbiology
4.7.1. Microbiology Market, 2018 - 2030 (USD Million)
4.8. Clinical Chemistry
4.8.1. Clinical Chemistry Market, 2018 - 2030 (USD Million)
4.9. Histology/Cytology
4.9.1. Histology/Cytology Market, 2018 - 2030 (USD Million)
4.10. Flow Cytometry
4.10.1. Flow Cytometry Market, 2018 - 2030 (USD Million)
4.11. Mass Spectroscopy
4.11.1. Mass Spectroscopy Market, 2018 - 2030 (USD Million)
4.12. Others
4.12.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. ASIA PACIFIC LABORATORY DEVELOPED TESTS MARKET: APPLICATION BUSINESS ANALYSIS
5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Oncology
5.4.1. Oncology Market, 2018 - 2030 (USD Million)
5.4.2. Companion Diagnostics
5.4.2.1. Companion Diagnostics Market, 2018 - 2030 (USD Million)
5.4.3. Genomics Sequencing and Others
5.4.3.1. Genomics Sequencing and Others Market, 2018 - 2030 (USD Million)
5.5. Genetic Disorders/Inherited Disease
5.5.1. Genetic Disorders/Inherited Disease Market, 2018 - 2030 (USD Million)
5.6. Infectious and Parasitic Diseases
5.6.1. Infectious and Parasitic Diseases Market, 2018 - 2030 (USD Million)
5.7. Immunology
5.7.1. Immunology Market, 2018 - 2030 (USD Million)
5.8. Endocrine
5.8.1. Endocrine Market, 2018 - 2030 (USD Million)
5.9. Nutritional and Metabolic Diseases
5.9.1. Nutritional and Metabolic Diseases Market, 2018 - 2030 (USD Million)
5.10. Cardiology
5.10.1. Cardiology Market, 2018 - 2030 (USD Million)
5.11. Mental/Behavioral Disorder
5.11.1. Mental/Behavioral Disorder Market, 2018 - 2030 (USD Million)
5.12. Pediatrics-Specific Testing
5.12.1. Pediatrics-Specific Testing Market, 2018 - 2030 (USD Million)
5.13. Hematology/General Blood Testing
5.13.1. Hematology/General Blood Testing Market, 2018 - 2030 (USD Million)
5.14. Bodily Fluid Analysis
5.14.1. Bodily Fluid Analysis Market, 2018 - 2030 (USD Million)
5.15. Toxicology
5.15.1. Toxicology Market, 2018 - 2030 (USD Million)
5.16. Others
5.16.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. ASIA PACIFIC LABORATORY DEVELOPED TESTS MARKET: COUNTRY ESTIMATES & TREND ANALYSIS
6.1. Country Market Share Analysis, 2024 & 2030
6.2. Country Market Dashboard
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. Japan
6.4.1. Key Country Dynamics
6.4.2. Regulatory Framework
6.4.3. Competitive Insights
6.4.4. Japan Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5. China
6.5.1. Key Country Dynamics
6.5.2. Regulatory Framework
6.5.3. Competitive Insights
6.5.4. China Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6. India
6.6.1. Key Country Dynamics
6.6.2. Regulatory Framework
6.6.3. Competitive Insights
6.6.4. India Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
6.7. South Korea
6.7.1. Key Country Dynamics
6.7.2. Regulatory Framework
6.7.3. Competitive Insights
6.7.4. South Korea Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8. Australia
6.8.1. Key Country Dynamics
6.8.2. Regulatory Framework
6.8.3. Competitive Insights
6.8.4. Australia Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
6.9. Thailand
6.9.1. Key Country Dynamics
6.9.2. Regulatory Framework
6.9.3. Competitive Insights
6.9.4. Thailand Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Quest Diagnostics Incorporated
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Abbott
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Guardant Health
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. NeoGenomics Laboratories
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Siemens Healthcare Private Limited
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. QIAGEN
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Illumina, Inc.
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.4. Strategic Initiatives
7.5.8. F. Hoffmann-La Roche Ltd
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Application
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
CHAPTER 3. ASIA PACIFIC LABORATORY DEVELOPED TESTS MARKET VARIABLES, TRENDS, & SCOPE
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
CHAPTER 4. ASIA PACIFIC LABORATORY DEVELOPED TESTS MARKET: TECHNOLOGY BUSINESS ANALYSIS
4.1. Technology Market Share, 2024 & 2030
4.2. Technology Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Technology, 2018 to 2030 (USD Million)
4.4. Immunoassays
4.4.1. Immunoassays Market, 2018 - 2030 (USD Million)
4.5. Hematology and Coagulation
4.5.1. Hematology and Coagulation Market, 2018 - 2030 (USD Million)
4.6. Molecular Diagnostics
4.6.1. Molecular Diagnostics Market, 2018 - 2030 (USD Million)
4.7. Microbiology
4.7.1. Microbiology Market, 2018 - 2030 (USD Million)
4.8. Clinical Chemistry
4.8.1. Clinical Chemistry Market, 2018 - 2030 (USD Million)
4.9. Histology/Cytology
4.9.1. Histology/Cytology Market, 2018 - 2030 (USD Million)
4.10. Flow Cytometry
4.10.1. Flow Cytometry Market, 2018 - 2030 (USD Million)
4.11. Mass Spectroscopy
4.11.1. Mass Spectroscopy Market, 2018 - 2030 (USD Million)
4.12. Others
4.12.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 5. ASIA PACIFIC LABORATORY DEVELOPED TESTS MARKET: APPLICATION BUSINESS ANALYSIS
5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Oncology
5.4.1. Oncology Market, 2018 - 2030 (USD Million)
5.4.2. Companion Diagnostics
5.4.2.1. Companion Diagnostics Market, 2018 - 2030 (USD Million)
5.4.3. Genomics Sequencing and Others
5.4.3.1. Genomics Sequencing and Others Market, 2018 - 2030 (USD Million)
5.5. Genetic Disorders/Inherited Disease
5.5.1. Genetic Disorders/Inherited Disease Market, 2018 - 2030 (USD Million)
5.6. Infectious and Parasitic Diseases
5.6.1. Infectious and Parasitic Diseases Market, 2018 - 2030 (USD Million)
5.7. Immunology
5.7.1. Immunology Market, 2018 - 2030 (USD Million)
5.8. Endocrine
5.8.1. Endocrine Market, 2018 - 2030 (USD Million)
5.9. Nutritional and Metabolic Diseases
5.9.1. Nutritional and Metabolic Diseases Market, 2018 - 2030 (USD Million)
5.10. Cardiology
5.10.1. Cardiology Market, 2018 - 2030 (USD Million)
5.11. Mental/Behavioral Disorder
5.11.1. Mental/Behavioral Disorder Market, 2018 - 2030 (USD Million)
5.12. Pediatrics-Specific Testing
5.12.1. Pediatrics-Specific Testing Market, 2018 - 2030 (USD Million)
5.13. Hematology/General Blood Testing
5.13.1. Hematology/General Blood Testing Market, 2018 - 2030 (USD Million)
5.14. Bodily Fluid Analysis
5.14.1. Bodily Fluid Analysis Market, 2018 - 2030 (USD Million)
5.15. Toxicology
5.15.1. Toxicology Market, 2018 - 2030 (USD Million)
5.16. Others
5.16.1. Others Market, 2018 - 2030 (USD Million)
CHAPTER 6. ASIA PACIFIC LABORATORY DEVELOPED TESTS MARKET: COUNTRY ESTIMATES & TREND ANALYSIS
6.1. Country Market Share Analysis, 2024 & 2030
6.2. Country Market Dashboard
6.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
6.4. Japan
6.4.1. Key Country Dynamics
6.4.2. Regulatory Framework
6.4.3. Competitive Insights
6.4.4. Japan Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
6.5. China
6.5.1. Key Country Dynamics
6.5.2. Regulatory Framework
6.5.3. Competitive Insights
6.5.4. China Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
6.6. India
6.6.1. Key Country Dynamics
6.6.2. Regulatory Framework
6.6.3. Competitive Insights
6.6.4. India Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
6.7. South Korea
6.7.1. Key Country Dynamics
6.7.2. Regulatory Framework
6.7.3. Competitive Insights
6.7.4. South Korea Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
6.8. Australia
6.8.1. Key Country Dynamics
6.8.2. Regulatory Framework
6.8.3. Competitive Insights
6.8.4. Australia Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
6.9. Thailand
6.9.1. Key Country Dynamics
6.9.2. Regulatory Framework
6.9.3. Competitive Insights
6.9.4. Thailand Laboratory Developed Tests Market Estimates And Forecasts, 2018-2030 (USD Million)
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. Quest Diagnostics Incorporated
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Abbott
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Guardant Health
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. NeoGenomics Laboratories
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Siemens Healthcare Private Limited
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. QIAGEN
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Illumina, Inc.
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.4. Strategic Initiatives
7.5.8. F. Hoffmann-La Roche Ltd
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
